Acute cardiorenal (type 1) Acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction Acute decompensated heart failure, acute coronary syndrome Chronic cardiorenal ...

In contrast to cardiorenal syndrome ... should the enhancement of cardiovascular death initiated by kidney disease be termed 'renocardiac syndrome'? As the kidney is the primary regulator of ...

TCT 72: Intravascular Imagining-Guided Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating Unprotected Left Main Stenosis: The Multicenter ROCK III Study Receive the ...

This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER, Nov. 06, 2024 ...

Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic ...

The SCD has been awarded U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation in three indications: Cardiorenal Syndrome – Left Ventricular Assist Device (CRS-LVAD) Adult Acute ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

Ardelyx is a biopharmaceutical company focusing on gastrointestinal and cardiorenal treatments. Its product portfolio ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Cardiorenal syndrome (CRS) commonly occurs during treatment of acute decompensated heart failure (ADHF) and is associated with poor clinical outcome. The pathophysiology of CRS entails a complex ...

Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among chronic kidney disease patients at risk for progression. HealthDay News — Empagliflozin continues to ...